Logo image of ORMP

ORAMED PHARMACEUTICALS INC (ORMP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ORMP - US68403P2039 - Common Stock

2.85 USD
+0.04 (+1.42%)
Last: 12/31/2025, 4:30:02 PM
3.12 USD
+0.27 (+9.47%)
After Hours: 12/24/2025, 7:53:55 PM
Fundamental Rating

4

ORMP gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While ORMP has a great health rating, there are worries on its profitability. ORMP is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ORMP was profitable.
ORMP had a negative operating cash flow in the past year.
ORMP had negative earnings in 4 of the past 5 years.
ORMP had a negative operating cash flow in each of the past 5 years.
ORMP Yearly Net Income VS EBIT VS OCF VS FCFORMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

ORMP has a Return On Assets of 19.89%. This is amongst the best in the industry. ORMP outperforms 96.86% of its industry peers.
Looking at the Return On Equity, with a value of 21.57%, ORMP belongs to the top of the industry, outperforming 91.62% of the companies in the same industry.
Industry RankSector Rank
ROA 19.89%
ROE 21.57%
ROIC N/A
ROA(3y)-10.8%
ROA(5y)-15.12%
ROE(3y)-11.25%
ROE(5y)-17.59%
ROIC(3y)N/A
ROIC(5y)N/A
ORMP Yearly ROA, ROE, ROICORMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

ORMP has a Profit Margin of 2192.60%. This is amongst the best in the industry. ORMP outperforms 99.48% of its industry peers.
ORMP does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 2192.6%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORMP Yearly Profit, Operating, Gross MarginsORMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

9

2. Health

2.1 Basic Checks

ORMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ORMP has less shares outstanding
Compared to 5 years ago, ORMP has more shares outstanding
There is no outstanding debt for ORMP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ORMP Yearly Shares OutstandingORMP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ORMP Yearly Total Debt VS Total AssetsORMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

ORMP has an Altman-Z score of 3.64. This indicates that ORMP is financially healthy and has little risk of bankruptcy at the moment.
ORMP has a better Altman-Z score (3.64) than 69.63% of its industry peers.
ORMP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.64
ROIC/WACCN/A
WACC8.69%
ORMP Yearly LT Debt VS Equity VS FCFORMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

ORMP has a Current Ratio of 22.24. This indicates that ORMP is financially healthy and has no problem in meeting its short term obligations.
ORMP has a better Current ratio (22.24) than 91.62% of its industry peers.
A Quick Ratio of 22.24 indicates that ORMP has no problem at all paying its short term obligations.
ORMP's Quick ratio of 22.24 is amongst the best of the industry. ORMP outperforms 92.15% of its industry peers.
Industry RankSector Rank
Current Ratio 22.24
Quick Ratio 22.24
ORMP Yearly Current Assets VS Current LiabilitesORMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

ORMP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 726.67%, which is quite impressive.
Looking at the last year, ORMP shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)726.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ORMP will show a very negative growth in Earnings Per Share. The EPS will decrease by -30.19% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y825.33%
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
EPS Next 5Y-30.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORMP Yearly Revenue VS EstimatesORMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2025 500K 1M 1.5M 2M 2.5M
ORMP Yearly EPS VS EstimatesORMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ORMP is valuated cheaply with a Price/Earnings ratio of 2.30.
Compared to the rest of the industry, the Price/Earnings ratio of ORMP indicates a rather cheap valuation: ORMP is cheaper than 97.91% of the companies listed in the same industry.
ORMP is valuated cheaply when we compare the Price/Earnings ratio to 26.51, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for ORMP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 2.3
Fwd PE N/A
ORMP Price Earnings VS Forward Price EarningsORMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORMP Per share dataORMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

ORMP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ORMP's earnings are expected to decrease with -66.87% in the coming years. This may justify a cheaper valuation.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ORMP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ORAMED PHARMACEUTICALS INC

NASDAQ:ORMP (12/31/2025, 4:30:02 PM)

After market: 3.12 +0.27 (+9.47%)

2.85

+0.04 (+1.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners18.24%
Inst Owner Change-0.22%
Ins Owners12.73%
Ins Owner Change0%
Market Cap113.43M
Revenue(TTM)2.00M
Net Income(TTM)43.85M
Analysts43.33
Price Target3.32 (16.49%)
Short Float %0.93%
Short Ratio1.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1852.45%
Min EPS beat(2)859.8%
Max EPS beat(2)2845.1%
EPS beat(4)3
Avg EPS beat(4)510.54%
Min EPS beat(4)-1762.75%
Max EPS beat(4)2845.1%
EPS beat(8)6
Avg EPS beat(8)-569.36%
EPS beat(12)10
Avg EPS beat(12)-366.78%
EPS beat(16)11
Avg EPS beat(16)-276.91%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)100%
EPS NQ rev (3m)100%
EPS NY rev (1m)476.47%
EPS NY rev (3m)476.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 2.3
Fwd PE N/A
P/S 56.72
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)1.24
EY43.51%
EPS(NY)-1.29
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0.05
BVpS5.11
TBVpS5.11
PEG (NY)0
PEG (5Y)N/A
Graham Number11.94
Profitability
Industry RankSector Rank
ROA 19.89%
ROE 21.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 2192.6%
GM N/A
FCFM N/A
ROA(3y)-10.8%
ROA(5y)-15.12%
ROE(3y)-11.25%
ROE(5y)-17.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.75%
Cap/Sales 0.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.24
Quick Ratio 22.24
Altman-Z 3.64
F-Score5
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)324.08%
Cap/Depr(5y)449.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)726.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
EPS Next Y825.33%
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
EPS Next 5Y-30.19%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.49%
OCF growth 3YN/A
OCF growth 5YN/A

ORAMED PHARMACEUTICALS INC / ORMP FAQ

What is the fundamental rating for ORMP stock?

ChartMill assigns a fundamental rating of 4 / 10 to ORMP.


What is the valuation status for ORMP stock?

ChartMill assigns a valuation rating of 4 / 10 to ORAMED PHARMACEUTICALS INC (ORMP). This can be considered as Fairly Valued.


How profitable is ORAMED PHARMACEUTICALS INC (ORMP) stock?

ORAMED PHARMACEUTICALS INC (ORMP) has a profitability rating of 3 / 10.


What are the PE and PB ratios of ORAMED PHARMACEUTICALS INC (ORMP) stock?

The Price/Earnings (PE) ratio for ORAMED PHARMACEUTICALS INC (ORMP) is 2.3 and the Price/Book (PB) ratio is 0.56.


How financially healthy is ORAMED PHARMACEUTICALS INC?

The financial health rating of ORAMED PHARMACEUTICALS INC (ORMP) is 9 / 10.